Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia. 2015

Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, College of Medicine, Taoyuan, Taiwan.

BACKGROUND To identify the clinical characteristics and risk factors for mortality of patients with cefepime-resistant Pseudomonas aeruginosa (FRPa) bacteremia. METHODS This retrospective study analyzed adult patients with FRPa bacteremia hospitalized between January 2006 and December 2011. RESULTS Seventy eight patients (46 male, 32 female; mean age: 72.2 ± 14.1 years) were included. Of them, 46 (59.0%) had ventilator use and 45 (57.7%) had intensive care unit stay. All the bacteremia episodes were health-care associated or hospital acquired, and 55.1% of FRPa blood isolates were multidrug resistant. The sources of bacteremia were identified in 42 patients (53.8%), with pneumonia being the most common one (28/42; 66.7%). The mean interval between admission and the sample date of the first FRPa-positive blood culture was 45.8 ± 52.6 days. The mean Pittsburgh bacteremia score was 5.0 ± 3.4. The 15-day and 30-day mortality rates were 50.0% and 65.4%, respectively. Patients (41; 52.6%) on appropriate antibiotic therapy within 72 hours of the first FRPa-positive blood culture had a higher 30-day survival rate than those without (48.8% vs. 18.9%, p = 0.011 by log-rank test). Multivariate analyses revealed that a higher Pittsburgh bacteremia score was an independent risk factor for either 15-day (p = 0.002) or 30-day mortality (p = 0.010), and appropriate antibiotic therapy within 72 hours was an independent protecting factor for either 15-day (p = 0.049) or 30-day mortality (p = 0.017). CONCLUSIONS FRPa bacteremia had a high mortality rate. The disease severity and appropriate antimicrobial therapy within 72 hours of positive blood culture were related to the patients' outcome.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077723 Cefepime A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA. Axépim,BMY 28142,BMY-28142,Cefepim,Cefepime Hydrochloride,Maxipime,Quadrocef,BMY28142
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
January 2012, Internal medicine (Tokyo, Japan),
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
January 2017, Antimicrobial agents and chemotherapy,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
January 2024, Pediatrics and neonatology,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
June 2011, Emerging infectious diseases,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
April 2024, Cureus,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
October 2015, Ophthalmology,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
April 2019, Archivos argentinos de pediatria,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
January 2010, Medicina (Kaunas, Lithuania),
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
March 2019, International journal of urology : official journal of the Japanese Urological Association,
Ting-Yi Su, and Jung-Jr Ye, and Po-Chang Hsu, and Hsuan-Feng Wu, and Ju-Hsin Chia, and Ming-Hsun Lee
February 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Copied contents to your clipboard!